Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma - LARVOL DELTA

MET-1, the active metabolite of erdosteine, enhances antibiotic activity against Pseudomonas aeruginosa in vitro. (ERS 2026) - "Table 1 Reduction in TOB IC50 when combined with 10mg/L MET-1 Metabolic activity Biofilm Biomass 24h 48h 24h 48h RP73 P<0.05 P<0.05 P<0.0001 PA01 P<0.001 P<0.0001 10 days post-infection with RP73, 40mg/kg TOB + 100mg/kg ERD showed a trend in reducing incidence of chronic colonization compared to TOB alone. Conclusion MET-1 significantly potentiated TOB activity versus planktonic and biofilm cultures of P.a. Preliminary in vivo data demonstrated trends for reduced incidence of colonization following combination therapy."

Preclinical • Infectious Disease • Respiratory Diseases

Erdosteine enhances antibiotic activity in reducing Streptococcus pneumoniae and non-typeable Haemophilus influenzae viability in biofilms (ERS 2026) - "Our findings indicated that the addition of erdosteine together with azithromycin decreased the viability of Spn in both mono- and co-species biofilms by up to 100-fold, whilst the addition of erdosteine with amoxicillin-clavulanic acid decreased Spn viability in co-species biofilms by 100-fold and mono-species biofilms by 10-fold, respectively. Similar trends were also observed with Met-1. Study results indicate that erdosteine, in combination with antibiotics, improves treatment outcomes for biofilm-mediated respiratory diseases, which are a significant global health burden."

Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Clinical Benefit Analysis of Erdosteine plus azithromycin in comparsion to standard care in preventing exacerbation in recovered cases of acute exacerbation of Bronchiectasis (ERS 2026) - "Long-term azithromycin plus erdosteine significantly reduces exacerbation frequency, severity, and duration, while increasing exacerbation-free periods in bronchiectasis, with greatest benefit in severe disease."

Clinical • Bronchiectasis • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases

Preventing mucus plugs in COPD: a potential role for erdosteine. (PubMed, Eur Respir J) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Targeting chronic mucus hypersecretion in respiratory diseases - focus on OPEP devices. (PubMed, Respir Med) - "Of these mucoactive drugs, N-acetylcysteine (NAC) and erdosteine are commonly used in India to manage CMH. The present review focuses on the prevalence of CMH in various CRDs, its impact on the natural history and disease progression in CRDs as well as various pharmacological and non-pharmacological therapies for CMH including published evidences. Special focus has been given to OPEP devices and therapeutic recommendations for practising clinicians have been provided."

Journal • Review • Infectious Disease • Respiratory Diseases

Approach to network failure due to intrinsic fluctuations. (PubMed, Phys Rev E) - "Further, the approach to network failure through these three regimes is shown to be qualitatively similar for square lattice, all-to-all, scale-free, and Erdos-Renyi networks. We obtain approximate analytical description of the approach to failure for an all-to-all network. This network failure scenario is also demonstrated on a real flight transportation network."

Journal

TAME-CLC: Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P=N/A | N=27000 | Active, not recruiting | Sponsor: Seoul National University

New trial • Chronic Obstructive Pulmonary Disease • Immunology • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non-Steroidal Anti-Inflammatory Drugs. (PubMed, Eur J Pain) - "Effective and well-tolerated treatments for chronic pain remain limited. Erdosteine is a clinically approved mucolytic with antioxidant and anti-inflammatory properties whose analgesic potential is largely unexplored. We show that oral erdosteine reduces inflammatory pain and allodynia without delaying recovery, unlike the NSAID diclofenac, which increased systemic markers of inflammation and prolonged pain duration. These findings identify erdosteine as a promising candidate for drug repurposing and support further investigation of its potential utility in pain management."

Clinical • Journal • Preclinical • Inflammation • Neuralgia • Pain • Respiratory Diseases • CXCL1 • IL1R1 • S100A8 • S100A9

Ecological niche and rickettsial risk mapping of Dermacentor nuttalli in Inner Mongolia, China. (PubMed, Front Cell Infect Microbiol) - "The moderate and high suitability areas in Xilingol, Ulanqab and Erdos all account for over 50%...Southern Xilingol, northern Ulanqab and northwestern Chifeng were identified as high-risk regions for Rickettsiae transmission. This study provides valuable references for the targeted surveillance and prevention of tick-borne rickettsiosis."

Journal • Lyme Disease

Mucoactive agents in bronchiectasis: a systematic review and meta-analysis. (PubMed, Eur Respir Rev) - "Pooled evidence did not show a reduction in exacerbations and FEV1 % pred improvements were small. Evidence certainty was low/very low, meaning overall clinical benefit remains uncertain, highlighting the need for targeted trials of specific agents and subgroups."

Clinical • Journal • Retrospective data • Review • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Pediatrics • Pulmonary Disease • Respiratory Diseases

A novel eco-friendly HPTLC approach for the simultaneous determination of erdosteine, ibuprofen and pseudoephedrine pharmaceutical combination. (PubMed, Sci Rep) - "The method's environmental sustainability was confirmed using the Analytical EcoScale, Analytical GREEnness (AGREE) calculator and Green Analytical Procedure Index (GAPI). Additionally, its overall whiteness profile was assessed using the Red-Green-Blue (RGB12) model approach, highlighting its analytical efficiency and eco-friendly design."

Journal • Infectious Disease • Pain • Respiratory Diseases

Erdosteine modulates surfactant-associated markers and preserves lung architecture in a preterm rat model compared with dexamethasone and betamethasone. (PubMed, Sci Rep) - "While not fully replicating the effects of antenatal corticosteroids, its anti-inflammatory and antioxidant properties suggest that it may serve as a supportive or complementary strategy for promoting fetal lung maturation. Further experimental and translational studies are warranted."

Journal • Preclinical • Inflammation • Pneumonia • ABCA3 • CASP3 • PCNA • SFTPA1

Mucus Plugs in COPD and Cardiovascular Mortality: An Emerging Risk Pathway and the Therapeutic Potential of Mucolytic Strategies. (PubMed, Respir Med) - "Among thiol-based mucolytics, erdosteine has been shown to reduce exacerbation frequency and duration...However, its comparative advantages over other agents remain uncertain. This narrative review summarizes the current evidence regarding the epidemiology, pathophysiology, and clinical implications of mucus plugging in COPD, with a focus on the proposed mucus plug-exacerbation-cardiovascular event axis and the potential role of mucus-directed therapies."

Journal • Review • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study. (clinicaltrialsregister.eu) - P4 | N=30 | Not yet recruiting | Sponsor: ASST Fatebenefratelli Sacco

New P4 trial • Chronic Obstructive Pulmonary Disease • Immune Modulation • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Immuno-inflammatory Response of Erdosteine in COPD (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Pierachille Santus, MD, PhD | Initiation date: Feb 2026 ➔ Sep 2026

Trial initiation date • Chronic Obstructive Pulmonary Disease • Immune Modulation • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Mapping the Landscape of Hutchinson-Gilford Progeria Syndrome Research: A Bibliometric Analysis (1995-2025). (PubMed, Ageing Res Rev) - "This bibliometric survey defines the age and focus of the research into HGPS, with published research being highly concentrated and collaborative and showing possible future research directions in regenerative therapy and epigenetic control. Although the modern knowledge about the progeria condition has grown significantly, there is still a significant drawback of the psychosocial research, prolonged therapy trials, and equity in research participation globally. The results thus highlight the need for multidisciplinary and cross-country collaboration in case science on progeria and wider related research on aging keeps evolving."

Journal • Review • Cardiovascular • Gene Therapies • Rare Diseases • LMNA

Sustainable multifaceted HPLC approach for concurrent quantitation of an octa-mixture used in upper respiratory therapy with a five-dimensional sustainability assessment. (PubMed, Sci Rep) - No abstract available

Journal

Using Nanopolymeric Microspheres for Enhanced Oil Recovery in a High-Salt Oil Reservoir in B‑3 Block, Erdos Basin, China. (PubMed, ACS Omega) - "The study also identified the optimal injection parameters: a concentration of 1250 mg/L, a rate of 0.3 mL/min, and a volume of 1.0 PV, which, under conditions of a permeability of 60.61 × 10-3 μm2 and a permeability contrast of 2.29, yielded the most pronounced profile control and displacement effect. This work demonstrates that the developed nanosphere system offers a robust and effective technical solution for the efficient development of challenging high-salinity, low-permeability reservoirs."

Journal

Head-to-head comparison of the MyGene human papillomavirus-sexually transmitted infection assay versus the Cobas 4800 human papillomavirus test for detecting high-grade cervical intraepithelial neoplasia. (PubMed, Int J Gynaecol Obstet) - "Our study indicated that MHSA could be considered a valuable option for cervical cancer screening in China."

Head-to-Head • Journal • Cervical Cancer • Gynecology • Infectious Disease • Oncology • Solid Tumor

Efficacy and safety of mucolytic agents in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis. (PubMed, BMC Pulm Med) - No abstract available

Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Immuno-inflammatory Response of Erdosteine in COPD (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Pierachille Santus, MD, PhD | Initiation date: Sep 2026 ➔ Feb 2026 | Trial primary completion date: Sep 2027 ➔ Feb 2027

Trial initiation date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immune Modulation • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Immuno-inflammatory Response of Erdosteine in COPD (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Pierachille Santus, MD, PhD

New trial • Chronic Obstructive Pulmonary Disease • Immune Modulation • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Nov 2025 ➔ Nov 2026

Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease

Glycation-mediated binding defect in human serum albumin transport of erdosteine: implications in diabetes. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "Elevated glucose levels in diabetic patients can induce structural and functional changes in proteins, potentially impacting the effective management of coexisting clinical conditions. Such changes may affect drug binding to transport proteins, thereby altering drug efficacy, clearance, and therapeutic outcomes."

Journal • Diabetes • Metabolic Disorders • Respiratory Diseases

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Tanta University

New P1/2 trial • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease